BR112018010535A2 - compostos peptídicos e conjugados peptídicos para o tratamento de câncer por quimioterapia com mediação por um receptor - Google Patents

compostos peptídicos e conjugados peptídicos para o tratamento de câncer por quimioterapia com mediação por um receptor

Info

Publication number
BR112018010535A2
BR112018010535A2 BR112018010535A BR112018010535A BR112018010535A2 BR 112018010535 A2 BR112018010535 A2 BR 112018010535A2 BR 112018010535 A BR112018010535 A BR 112018010535A BR 112018010535 A BR112018010535 A BR 112018010535A BR 112018010535 A2 BR112018010535 A2 BR 112018010535A2
Authority
BR
Brazil
Prior art keywords
peptide
cancer
treatment
compounds
receptor
Prior art date
Application number
BR112018010535A
Other languages
English (en)
Inventor
Larocque Alain
Annabi Borhane
Charfi Cyndia
Currie Jean-Christophe
Demeule Michel
Béliveau Richard
Original Assignee
Transfert Plus Sec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transfert Plus Sec filed Critical Transfert Plus Sec
Publication of BR112018010535A2 publication Critical patent/BR112018010535A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/083—Neurotensin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente descrição refere-se a compostos peptídicos e compostos conjugados, processos, métodos e uso dos mesmos para o tratamento do câncer e aumento da internalização celular dos referidos compostos peptídicos. os compostos peptídicos são selecionados do seguinte grupo consistindo de; gvrakagvrnmfksesy como estabelecido na seq id no: 9; gvrakagvrn(nle)fksesy como estabelecido na seq id no: 10; e ykslrrkaprwdaplrdpalrqll como estabelecido na seq id no: 11; e em que pelo menos um grupo protetor e/ou pelo menos um agente de marcação é ligado ao referido composto peptídico.
BR112018010535A 2015-11-24 2016-11-24 compostos peptídicos e conjugados peptídicos para o tratamento de câncer por quimioterapia com mediação por um receptor BR112018010535A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562259178P 2015-11-24 2015-11-24
PCT/CA2016/051379 WO2017088058A1 (en) 2015-11-24 2016-11-24 Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy

Publications (1)

Publication Number Publication Date
BR112018010535A2 true BR112018010535A2 (pt) 2018-11-13

Family

ID=58762819

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018010535A BR112018010535A2 (pt) 2015-11-24 2016-11-24 compostos peptídicos e conjugados peptídicos para o tratamento de câncer por quimioterapia com mediação por um receptor

Country Status (14)

Country Link
US (3) US11034727B2 (pt)
EP (2) EP3925969A1 (pt)
JP (2) JP6810146B2 (pt)
CN (2) CN108473541B (pt)
AU (2) AU2016358324B2 (pt)
BR (1) BR112018010535A2 (pt)
CA (2) CA3006313C (pt)
DK (1) DK3380495T3 (pt)
ES (1) ES2882634T3 (pt)
PL (1) PL3380495T3 (pt)
PT (1) PT3380495T (pt)
SI (1) SI3380495T1 (pt)
WO (1) WO2017088058A1 (pt)
ZA (1) ZA201804117B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3006313C (en) 2015-11-24 2020-02-11 Transfert Plus, S.E.C. Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
US20200157151A1 (en) * 2017-05-24 2020-05-21 Transfert Plus, S.E.C. Peptide compounds, conjugate compounds and uses thereof for treating inflammatory diseases
US11389460B2 (en) 2017-09-15 2022-07-19 City Of Hope Methods and compositions for treating endometrial cancer
EP3844190A4 (en) * 2018-08-24 2022-06-08 Transfert Plus, S.E.C. METHODS AND COMPOUNDS FOR TARGETING SORTILIN RECEPTORS AND INHIBITING VASCULOGEN MIMETICISM
EP3986921A2 (en) * 2019-06-20 2022-04-27 Aarhus Universitet Sorcs2 crystal structure and uses thereof
CN114980932A (zh) * 2019-12-06 2022-08-30 瑟瑞技术公司 Sortilin结合缀合化合物、其组合物及其用于治疗癌症的用途
US20230338555A1 (en) * 2020-05-18 2023-10-26 Ionis Pharmaceuticals, Inc. Conjugated oligonucleotides and uses thereof
KR20230167033A (ko) * 2021-02-26 2023-12-07 트랑스페르 플러스, 에스.으.쎄. 암 줄기 세포를 표적화하기 위한 방법 및 소르틸린 결합 접합체 화합물
CN116731113A (zh) * 2022-03-01 2023-09-12 上海智肽生物科技有限公司 针对sort1的多肽化合物及其药物偶联物
WO2024103161A1 (en) * 2022-11-14 2024-05-23 Theratechnologies Inc. Drug conjugate compounds for stimulating the antitumor immune response
CN117904303B (zh) * 2024-03-18 2024-06-18 湖南宏雅基因技术有限公司 Sorcs1基因甲基化和pax1基因甲基化联合诊断的检测引物探针组在制备宫颈癌诊断产品中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
FI101678B1 (fi) 1990-12-31 1998-08-14 Akzo Nv Happolabiileja kytkentämolekyylejä
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand
ES2311560T3 (es) 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
US8344211B2 (en) * 2008-08-13 2013-01-01 Ceres, Inc. Plant nucleotide sequences and corresponding polypeptides
TW200634019A (en) 2004-12-21 2006-10-01 Wyeth Corp Thienoisoquinoline-phenylsulfonamides and their use as er-nfkb inhibitors
JP5123936B2 (ja) * 2006-05-30 2013-01-23 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 認知症の検出および治療
EP2077278A1 (fr) * 2007-12-21 2009-07-08 Centre National de la Recherche Scientifique (CNRS) Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques
EP2274327B1 (en) * 2008-04-27 2019-03-27 H. Lundbeck A/S Crystal structure of human sortilin and uses thereof for identifying ligands to sortilin
US20120039865A1 (en) * 2008-08-19 2012-02-16 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
AU2009322043A1 (en) 2008-12-05 2011-07-07 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
US8147849B2 (en) 2009-02-20 2012-04-03 Novartis Ag Protective antigens for group B Streptococcus hypervirulent strains
CN102596993A (zh) 2009-07-02 2012-07-18 安吉奥开米公司 多聚体肽结合物以及其应用
CA2786255A1 (en) 2009-12-31 2011-07-07 Organomed Corporation Formulations from natural products, turmeric, and aspirin
EP2740726A1 (en) * 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
PT3280441T (pt) * 2015-04-07 2021-11-30 Alector Llc Anticorpos anti-sortilina e métodos para a sua utilização
CA3006313C (en) 2015-11-24 2020-02-11 Transfert Plus, S.E.C. Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
US20200157151A1 (en) * 2017-05-24 2020-05-21 Transfert Plus, S.E.C. Peptide compounds, conjugate compounds and uses thereof for treating inflammatory diseases
EP3844190A4 (en) * 2018-08-24 2022-06-08 Transfert Plus, S.E.C. METHODS AND COMPOUNDS FOR TARGETING SORTILIN RECEPTORS AND INHIBITING VASCULOGEN MIMETICISM

Also Published As

Publication number Publication date
CA3071494C (en) 2021-12-14
CA3006313C (en) 2020-02-11
CA3071494A1 (en) 2017-06-01
SI3380495T1 (sl) 2022-01-31
CN108473541B (zh) 2023-05-12
EP3925969A1 (en) 2021-12-22
ES2882634T3 (es) 2021-12-02
CA3006313A1 (en) 2017-06-01
WO2017088058A1 (en) 2017-06-01
US20220356209A1 (en) 2022-11-10
JP6810146B2 (ja) 2021-01-06
AU2021201085A1 (en) 2021-03-11
CN108473541A (zh) 2018-08-31
AU2016358324A1 (en) 2018-07-05
EP3380495B1 (en) 2021-05-19
US20240199695A1 (en) 2024-06-20
JP7095035B2 (ja) 2022-07-04
AU2021201085B2 (en) 2023-01-19
JP2019501141A (ja) 2019-01-17
ZA201804117B (en) 2022-08-31
CN116478245A (zh) 2023-07-25
PT3380495T (pt) 2021-08-19
EP3380495A4 (en) 2019-02-27
PL3380495T3 (pl) 2021-12-13
AU2016358324B2 (en) 2021-03-11
US20200392184A1 (en) 2020-12-17
JP2020189867A (ja) 2020-11-26
DK3380495T3 (da) 2021-08-16
EP3380495A1 (en) 2018-10-03
US11034727B2 (en) 2021-06-15
US11780882B2 (en) 2023-10-10

Similar Documents

Publication Publication Date Title
BR112018010535A2 (pt) compostos peptídicos e conjugados peptídicos para o tratamento de câncer por quimioterapia com mediação por um receptor
BR112018015419A2 (pt) degradantes seletivos de receptor de estrogênio e os usos dos mesmos
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
BR112015014333A8 (pt) compostos antivirais, seu uso e composição farmacêutica que os compreende
MX2019005911A (es) Anticuerpos anti_cd137 novedosos y usos de estos.
BR112019003866A2 (pt) adenovírus estimulado com fragmento de mab biespecífico com redirecionamento de células t (bite)
BR112019002687A2 (pt) receptores de antígeno quimérico que direcionam bcma e métodos de uso dos mesmos
BR112019022495A2 (pt) Conjugados de anticorpo que compreendem agonista de receptor similar a toll e terapias de combinação
BR112018070161A2 (pt) moduladores de receptores de estrogênio
BR112017003582A2 (pt) anticorpos, composições e usos
BR112017027414A2 (pt) Derivados hidroxiéster, processo para prepará- los e composições farmacêuticas os contendo
BR112016003417A2 (pt) diacorpo otimizado por sequência capaz de se ligar especificamente a um epitopo de cd123 e a um epitopo de cd3, diacorpo biespecífico capaz de se ligar especificamente a um epitopo de cd123 e a um epitopo de cd3, composição farmacêutica, e uso da composição farmacêutica
BR112017012944A2 (pt) ?anticorpo, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e, método para prevenção, tratamento ou melhoria de pelo menos um sintoma de infecção de influenza?
BR112018015238A2 (pt) conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição
BR112016020752A2 (pt) ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente?
BR112016024370A2 (pt) conjugados de anticorpo-fármaco com alto carregamento de fármaco
BR112012026953A8 (pt) Composto, uso de um composto, composição farmacêutica, e processo para preparar uma composição farmacêutica
CL2017001336A1 (es) Nuevos aminoácidos ester fosforamidatos 2' y/o 5', 3' deoxiadenosina derivativos como compuestos anticancerígenos
BR112015020290A2 (pt) métodos para tratar um câncer, para prevenir câncer, para inibir proliferação, para tratar terapeuticamente um mamífero, para tratar uma disfunção, para reduzir níveis de proteína spp1, para tratar terapeuticamente um câncer, para tratar um indivíduo e para inibir proliferação celular, artigo, anticorpos e usos
BR112017025711A2 (pt) ?composições, processo para preparação de siloxanos modificados por poliéter e uso das composições inovadoras?
BR112018007960A2 (pt) conjugado, proteína pcrv, composição imunogênica, métodos de preparação de uma composição imunogênica, de tratamento e de produção de um bioconjugado, polinucleotídeo, vetor, célula hospedeira, e, bioconjugado.
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112015022780A2 (pt) reticuladores de produto químico
BR112015001096A2 (pt) derivados de di e tri-heteroaril como inibidores de agregação de proteína
BR112017010832A2 (pt) composições de aminoácido para o tratamento de sintomas de doença

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]